Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens ; volume:21 ; number:1 ; day:22 ; month:5 ; year:2023 ; pages:1-14 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (22.5.2023), 1-14, 12.2023
- Urheber
-
Shen, Luhui
Brown, Justin R.
Johnston, Stephen Albert
Altan, Mehmet
Sykes, Kathryn F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04172-w
- URN
-
urn:nbn:de:101:1-2023091011503779265400
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shen, Luhui
- Brown, Justin R.
- Johnston, Stephen Albert
- Altan, Mehmet
- Sykes, Kathryn F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
FMCGP: frameshift mutation cartesian genetic programming
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
FMCGP: frameshift mutation cartesian genetic programming
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
FMCGP: frameshift mutation cartesian genetic programming
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies